Option Care Health, Inc. (NASDAQ:OPCH), the largest independent provider of home and alternate site infusion therapy in the U.S., reported second-quarter results that beat analyst expectations, supported by double-digit revenue growth across its service lines.
For the quarter ended June, the company posted revenue of $1.42 billion, marking a 15.4% year-over-year increase and exceeding the $1.35 billion consensus forecast. Revenue growth was fueled by broad-based strength in its infusion services segment.
Adjusted earnings per share came in at $0.41, ahead of the $0.38 estimate. While gross profit climbed 7.9% to $269 million, the gross margin narrowed to 19%, down from 20.3% a year ago due to rising operating costs.
“I am proud of the second quarter performance and the Option Care Health team’s ability to show resilience in a dynamic marketplace,” said John C. Rademacher, Chief Executive Officer. “We continue to execute on opportunities to provide strong clinical outcomes while helping reduce the total cost of care.”
The company also reported a 5.2% increase in adjusted EBITDA, which rose to $114 million from $108.4 million in the same period last year. However, operating cash flow declined to $90.3 million, compared to $195.7 million a year ago. During the quarter, the company also repurchased approximately $50 million worth of stock.
Looking forward, Option Care Health raised its full-year 2025 guidance, projecting revenue between $5.5 billion and $5.65 billion, which aligns with the $5.54 billion analyst consensus. The company expects adjusted EPS in the range of $1.65 to $1.72, compared to expectations of $1.68, and adjusted EBITDA between $465 million and $475 million.
Option Care Health stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.